Income Statement Kintor Pharmaceutical Limited OTC Markets
Stocks
KNTPF
KYG5273B1077
Biotechnology & Medical Research
|
Market Closed -
OTC Markets
18:46:29 12/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.2399 USD | +39.48% |
|
0.00% | +11.06% |
| 08-19 | Kintor Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 06-11 | Kintor Pharma Posts Positive Interim Safety Data for Whitening Agent KT-939 | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 34.23M | - | - | 5M | 32.68M | |||||
Other Revenues, Total | - | - | - | - | - | |||||
Total Revenues | 34.23M | - | - | 5M | 32.68M | |||||
Cost of Goods Sold, Total | - | - | 42.23M | 3.52M | 24.64M | |||||
Gross Profit | 34.23M | - | -42.23M | 1.48M | 8.04M | |||||
Selling General & Admin Expenses, Total | 118M | 153M | 96.03M | 88M | 97.88M | |||||
Provision for Bad Debts | - | - | - | 1.21M | -900K | |||||
R&D Expenses | 768M | 828M | 939M | 71.49M | 85.5M | |||||
Other Operating Expenses | -16.96M | -11.42M | -7.49M | -17.43M | -1.89M | |||||
Other Operating Expenses, Total | 869M | 969M | 1.03B | 143M | 181M | |||||
Operating Income | -835M | -969M | -1.07B | -142M | -173M | |||||
Interest Expense, Total | -2.49M | -8.19M | -9.69M | -9.28M | -3.94M | |||||
Interest And Investment Income | 12.05M | 6.88M | 13.08M | 4.21M | 108K | |||||
Net Interest Expenses | 9.56M | -1.3M | 3.39M | -5.07M | -3.84M | |||||
Income (Loss) On Equity Invest. | - | -568K | 52K | -1.43M | 766K | |||||
Currency Exchange Gains (Loss) | -17.62M | 16.33M | -3.13M | 3.73M | -39K | |||||
Other Non Operating Income (Expenses) | - | - | - | - | - | |||||
EBT, Excl. Unusual Items | -843M | -955M | -1.07B | -145M | -176M | |||||
Gain (Loss) On Sale Of Investments | 777K | 2M | 491K | 1K | - | |||||
Gain (Loss) On Sale Of Assets | -106K | -620K | 10K | 2.52M | -60K | |||||
Asset Writedown | - | - | - | -13.25M | -27.24M | |||||
Other Unusual Items | - | - | - | - | - | |||||
EBT, Incl. Unusual Items | -842M | -953M | -1.07B | -155M | -203M | |||||
Income Tax Expense | - | 1.08M | -8.04M | 18K | -2.85M | |||||
Earnings From Continuing Operations | -842M | -954M | -1.06B | -155M | -200M | |||||
Net Income to Company | -842M | -954M | -1.06B | -155M | -200M | |||||
Net Income - (IS) | -842M | -954M | -1.06B | -155M | -200M | |||||
Net Income to Common Incl Extra Items | -842M | -954M | -1.06B | -155M | -200M | |||||
Net Income to Common Excl. Extra Items | -842M | -954M | -1.06B | -155M | -200M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -2.36 | -2.53 | -2.47 | -0.36 | -0.44 | |||||
Basic EPS - Continuing Operations | -2.36 | -2.53 | -2.47 | -0.36 | -0.44 | |||||
Basic Weighted Average Shares Outstanding | 356M | 377M | 429M | 431M | 450M | |||||
Net EPS - Diluted | -2.36 | -2.53 | -2.47 | -0.36 | -0.44 | |||||
Diluted EPS - Continuing Operations | -2.36 | -2.53 | -2.47 | -0.36 | -0.44 | |||||
Diluted Weighted Average Shares Outstanding | 356M | 377M | 429M | 431M | 450M | |||||
Normalized Basic EPS | -1.48 | -1.58 | -1.56 | -0.21 | -0.24 | |||||
Normalized Diluted EPS | -1.48 | -1.58 | -1.56 | -0.21 | -0.24 | |||||
Supplemental Items | ||||||||||
EBITDA | -828M | -956M | -1.06B | -129M | -141M | |||||
EBITA | -835M | -969M | -1.07B | -142M | -155M | |||||
EBIT | -835M | -969M | -1.07B | -142M | -173M | |||||
EBITDAR | -827M | -955M | -1.06B | -128M | -140M | |||||
Total Revenues (As Reported) | - | - | - | - | - | |||||
Effective Tax Rate - (Ratio) | - | -0.11 | 0.75 | -0.01 | 1.41 | |||||
Total Current Taxes | - | 1.08M | -266K | 18K | 1.51M | |||||
Deferred Domestic Taxes | - | - | - | - | - | |||||
Total Deferred Taxes | - | - | -7.78M | - | -4.36M | |||||
Normalized Net Income | -527M | -597M | -668M | -90.34M | -110M | |||||
Interest Capitalized | 4.4M | 2.37M | 2.7M | - | - | |||||
Interest on Long-Term Debt | 4.57M | 2.82M | 3.03M | 162K | 52K | |||||
Supplemental Operating Expense Items | ||||||||||
Marketing Expenses | 14.7M | 20.33M | 6.98M | 26.56M | 41.2M | |||||
Selling and Marketing Expenses | 14.7M | 20.33M | 6.98M | 26.56M | 41.17M | |||||
General and Administrative Expenses | 102M | 131M | 88.36M | 60.7M | 56.72M | |||||
Research And Development Expense From Footnotes | 768M | 828M | 939M | 78.14M | 87.39M | |||||
Net Rental Expense, Total | 1.36M | 1.22M | 682K | 733K | 524K | |||||
Imputed Operating Lease Interest Expense | 395K | 461K | 250K | 281K | 151K | |||||
Imputed Operating Lease Depreciation | 970K | 756K | 432K | 452K | 373K | |||||
Maintenance & Repair Expenses, Total | - | - | - | - | - | |||||
Stock-Based Comp., R&D Exp. (Total) | 19.93M | 57.23M | 19.77M | -11.28M | -1.38M | |||||
Stock-Based Comp., S&M Exp. (Total) | - | - | - | - | -30K | |||||
Stock-Based Comp., G&A Exp. (Total) | 11.95M | 29.79M | 10.66M | 2.02M | 1.73M | |||||
Stock-Based Comp., Other (Total) | 5.47M | 8.62M | - | - | - | |||||
Total Stock-Based Compensation | 37.35M | 95.64M | 30.42M | -9.26M | 321K |
Select your edition
All financial news and data tailored to specific country editions
















